Biosensors for Point-of-Care Diagnostics Market

The Biosensors for Point-of-Care Diagnostics Market is valued at USD 16.8 Bn in 2026 and is projected to reach USD 27.6 Bn, growing at a CAGR of 4% by 2033. 

Market Analysis in Brief

The global demand, manufacturing, and sales of biosensor products specially created for use in point-of-care (POC) settings is collectively referred to as the biosensors for point-of-care diagnostics market. Various biosensors, including glucose sensors for managing diabetes, pregnancy test strips, infectious illness detection tools, cardiac indicators, and other specialised biosensors that facilitate quick and precise diagnosis are widely available on the market. The growing need for early disease detection, the rising prevalence of chronic diseases, growing inclination toward personalised medication, and the aim to increase healthcare accessibility and cost-effectiveness are some of the key growth indicators for biosensors in POC diagnostics.

Key Report Findings

• The global biosensors for point-of-care diagnostics market will expand at a significant rate of 8.5% CAGR between 2023 and 2030.
• The demand for biosensors for point-of-care diagnostics is rising due to the growing prevalence of chronic diseases.
• Demand for molecular diagnostic biosensors remains higher in the biosensors for point-of-care diagnostics market.
• The glucose testing category held the highest biosensors for point-of-care diagnostics market revenue share in 2022.
• Asia Pacific will continue to lead its way, whereas North America biosensors for point-of-care diagnostics market will experience the strongest growth till 2030.

Growth Drivers

Growing Prevalence of Chronic Diseases

The market for biosensors for point-of-care diagnostics is significantly driven by the rising prevalence of chronic diseases. Diabetes, cardiovascular conditions like hypertension, respiratory conditions like asthma, and specific cancer stages are a few examples of chronic diseases. To control their progression and treatment, chronic diseases need continuous monitoring and supervision. Biosensors is becoming an effective technique to track different biomarkers linked to chronic illnesses, to deliver quick and real-time findings. The need for ongoing monitoring drives the use of biosensors in POC diagnostics.

Rise in chronic diseases has sparked a move towards personalised medicines tailored as per patient characteristics. Healthcare professionals can choose a personalised course of treatment and modify medicines as necessary due to the real-time data on biomarkers provided by biosensors. Companies engaged in researching and producing biosensors for POC diagnostics have a sizable market opportunity due to the rising prevalence of chronic diseases worldwide. As a result, there have been more investments made in the area of research and innovation.

Increased Healthcare Access and Affordability

The usage of biosensors for POC diagnostics is mostly influenced by improved access to healthcare services and affordable diagnostic options. POC diagnostics, with biosensors, can be used in remote or resource-constrained locations with limited access to centralised laboratories or medical facilities. These tools enable medical personnel to conduct tests on patients on-site, expanding access to healthcare and providing crucial diagnostic services to underprivileged communities.

The benefit of POC diagnostics using biosensors is that there is no need for several visits or protracted test results waiting periods. This ease not only increases patient happiness but also makes sure that healthcare professionals make decisions on time. The lower cost of biosensors enables patients to make health investments and start using self-monitoring techniques. Biosensor-based home healthcare enables patients to regularly monitor their health conditions, enabling the early identification of possible problems and better disease management.

Market Challenges

Competing Diagnostic Technologies

The growth of the market for biosensors for point-of-care diagnostics may be restrained by rival diagnostic technologies. There are other point-of-care diagnostics options apart from biosensors, and these alternatives are known to compete with existing diagnostic technologies. Numerous conventional point-of-care diagnostic techniques are well-established in healthcare systems and have been in use for a long time. It may be difficult for biosensors to replace certain techniques, such as lateral flow assays, immunoassays, and molecular diagnostics, because they may be embedded strongly in clinical procedures.

Some competing technologies might be less expensive or might not need a lot of infrastructure changes to be implemented. If healthcare facilities already have functional systems employing alternative diagnostic techniques in place, they could be reluctant to invest in biosensors. The ability to identify numerous analytes or pathogens in a single test is a feature that certain competing technologies offer, which might be useful in some diagnostic situations. The deployment of biosensors in some applications may be hampered by their relatively constrained test menu.

Market Opportunities

Under-resourced, Underserved Areas Hold Untapped Opportunity

Biosensor development and manufacturing can be costly, especially when using cutting-edge technology and premium materials. Because of their higher prices, they may not be as affordable as they may be, especially in environments with few resources where affordable diagnostic options are essential. POC diagnostics can offer vital medical services to remote or under-resourced locations with little access to lab infrastructure. Biosensors have an opportunity to increase diagnostic capabilities for underserved populations, particularly those built for mobility and ease of use.

Overview of Key Segments

Molecular Diagnostic Biosensors Dominant Product Segment

The molecular diagnostic biosensors segment will dominate the global biosensors for point-of-care diagnostics market over the forecast period. These biosensors identify and measure particularly nucleic acids, proteins, or other substances at the molecular level and provide precise results in less time.

The quick identification of infectious disorders brought on by viruses, bacteria, and other pathogens is made possible by the widespread use of molecular diagnostic biosensors. These biosensors can recognize specific genetic material (DNA or RNA) that is particular to the infections, enabling early diagnosis and prompt implementation of effective treatments. Examples are COVID-19, influenza, HIV, hepatitis, and tuberculosis biosensors.

Specific biomarkers connected to cancer types can be found using molecular diagnostic biosensors. These biosensors help in the early detection of cancer, evaluate the effectiveness of treatment, and determine the course of the disease by identifying proteins or genetic alterations linked to the disease.

Demand for Glucose Testing Continues to Heighten

The Glucose Testing segment is expected to be the fastest-growing segment of the biosensors for the point-of-care diagnostics market. Diabetes is a chronic disorder marked by high blood sugar levels. Biosensors for point-of-care diagnostics have revolutionised glucose testing and are essential to managing the condition. In glucose testing, glucose biosensors are frequently used to track blood sugar levels. This data is essential for managing diabetes. Blood glucose meters and continuous glucose monitoring (CGM) systems are two examples of diabetes monitoring devices that incorporate glucose biosensors. These tools make it comfortable and frequent for diabetic patients to assess their blood glucose levels, giving them the desired information for making prudent choices about their food, medications, and physical activity.

The development of non-invasive glucose biosensors that can test blood sugar levels without requiring a fingerstick is still under investigation. These systems may use methods like transdermal sensing, optical sensors, or saliva-based testing to deliver glucose readings without extracting blood. Personalised diabetes management is made possible by glucose biosensors, which give patients and healthcare professionals access to real-time information on glucose changes. This information aids people in altering their lifestyles, adjusting medication dosages, and lowering their risk of hypoglycemia or hyperglycemia.

Growth Opportunities Across Regions

Asia Pacific Represents the Largest Regional Market

During the forecast period, Asia Pacific is expected to dominate the biosensors for the point-of-care diagnostics market. The adoption of cutting-edge medical technologies, such as biosensors, has been aggressively promoted in many Asia Pacific nations. Government initiatives, financing, and encouraging legislation have significantly aided the development of the biosensors industry for point-of-care diagnostics.

Wearable biosensors for point-of-care diagnostics have become increasingly popular in the Asia Pacific region. These wearable devices like smartwatches and fitness bands, incorporate biosensor technology to continuously monitor vital signs and other health factors, giving consumers insightful data about their health.

In China, using biosensors for home-based point-of-care diagnostics has become more common. The industry is showcasing expansion because of factors including the accessibility and convenience of doing tests at home as well as the capability of remotely sharing data with medical specialists.

North American Market Set for Fastest Growth

The market for biosensors for point-of-care diagnostics across North America will display a significant CAGR during the forecast period. Telemedicine and virtual care have grown extensively in North America, creating opportunities for biosensors to be integrated into telemedicine platforms. Transparent data exchange between telemedicine providers and biosensors can improve virtual consultations and facilitate quick decision-making.  

Rapid and precise point-of-care testing is becoming increasingly necessary in non-traditional healthcare settings like pharmacies, schools, workplaces, and community clinics in North America. By delivering immediate diagnosis in certain circumstances, biosensors can provide useful solutions.

In the United States, mobile health platforms are increasingly integrating biosensors. Due to the seamless data transfer and analysis made possible by this integration, both patients and healthcare professionals are now better equipped to keep track of their health problems and effectively treat chronic diseases.

Biosensors for Point-of-Care Diagnostics Market: Competitive Landscape

Some of the leading players at the forefront in the biosensors for point-of-care diagnostics include Danaher Corporation, Bio-Rad Laboratories Inc., Zimmer & Peacock AS, Medtronic plc, Koninklijke Philips N.V., Abbott Laboratories, Biosensors International Group, Ltd., DuPont, Johnson & Johnson, LifeScan, Inc., QTL Biodetection LLC, Nova Biomedical, Roche, and Siemens Healthineers AG.

Leading Companies

• Danaher Corporation
• Bio-Rad Laboratories Inc.
• Zimmer & Peacock AS
• Medtronic plc
• Koninklijke Philips N.V.
• Abbott Laboratories
• Universal Biosensors, Inc.
• Biosensors International Group, Ltd.
• Johnson & Johnson
• Masimo Corporation
• QTL Biodetection LLC
• Nova Biomedical
• Innovative Sensor Technology IST AG
• Siemens Healthineers AG
• Hoffmann-La Roche Ltd.

Recent Notable Developments

In November 2022, The Ministry of Food and Drug Safety (MFDS) granted Boditech Med Inc. authorisation to utilize the Boditech Quick COVID-19 Ag Saliva test domestically. Quick COVID-19 Ag Saliva is an enhanced COVID-19 Ag at-home test that uses saliva to collect data in 15 minutes and detects all COVID-19 viral types, including the Omicron form.

In October 2022, SARS-CoV-2 Rapid Antibody Test 2.0 for point-of-care settings was released, according to F. Hoffmann-La Roche Ltd. The test has a sensitivity of 95.83%.

In September 2022, Sansure Biotech, an IVD solution supplier, and QuantuMDx Group Ltd., a U.K.-based medical technology business, announced a partnership. The partnership aims to hasten the Q-POC platform's and related assays' commercialisation in China.

In January 2021, Roche and Sysmex signed a Global Business Partnership Agreement (GBP) to provide hematology diagnostic solutions. In line with the new agreement, clinical decision-making and customer experience will be enhanced with the use of IT technologies. The successful, long-standing relationship keeps developing and introducing new hematology diagnostic techniques to labs worldwide.

The Global Biosensors for Point-of-Care Diagnostics Market is Segmented as Below:

By Product

• Biomarkers
• Bioreceptors
• Molecular Diagnostic Biosensors

By Transducer

• Thermal
• Piezoelectric
• Electrochemical
• Optical

By Application

• Fertility/Pregnancy
• Glucose Testing
• Hb1Ac Testing
• Infectious Disease
• Cardiac Markers
• Cancer Markers
• Drugs of Abuse Testing
• Coagulation Testing
• Hormone Analysis
• Others

By End User

• Clinics
• Hospitals
• Home Care Service Providers
• Assisted Living Healthcare Centres
• Research Laboratory

By Geographic Coverage

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa